Premium
Evolution of histamine H 2 ‐receptor antagonist use in an ambulatory elderly population: A 14‐year overview
Author(s) -
Stewart Ronald B.,
Neal Carolyn,
Padgett Phillip D.,
Marks Ronald G.,
Hale William E.
Publication year - 1995
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.2630040310
Subject(s) - medicine , ranitidine , cimetidine , histamine , antagonist , ambulatory , population , histamine h1 receptor , pharmacology , receptor , environmental health
The purpose of this study was to determine the frequency and pattern of histamine H 2 ‐receptor antagonist drug use in an ambulatory elderly population of individuals over 65 years of age from 1978 to 1992. A longitudinal health screening programme of ambulatory elderly participants was employed to conduct a series of cross‐sectional studies over a 14‐year period. Participants in the first period (1978–79) included 855 (37.1%) men and 1448 (62.9%) women. The use of histamine H 2 ‐receptor antagonist increased from 0.8% of the population in the 1978–79 period to 7.0% in the 1991–92 period. There was no statistically significant correlation between drug use and age (p = 0.8114) or sex (p = 0.9229) at the 1991–92 time period. In the 1991–92 time period, cimetidine and ranitidine combined, accounted for 86.0% of all reported histamine H 2 ‐receptor antagonist. Over the 14‐year period of study there has been a nearly constant increase of histamine H 2 ‐receptor antagonist use in this elderly population.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom